Bulk Manufacturer of Controlled Substances Application: Noramco, Inc., 31227 [2020-11077]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 100 / Friday, May 22, 2020 / Notices
samer.musallam@usdoj.gov, Email:
lowell.stern@usdoj.gov.
Attorneys for Plaintiff United States
Active Pharmaceutical Ingredient (API)
for supply to its customers. In reference
to drug codes 7360 (Marihuana) and
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture
these drugs as synthetics. No other
activities for these drug codes are
authorized for this registration. This
notice does not constitute an evaluation
or determination of the merits of the
company’s application.
[FR Doc. 2020–11073 Filed 5–21–20; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–645]
Bulk Manufacturer of Controlled
Substances Application: Noramco, Inc.
ACTION:
Notice of application.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–11077 Filed 5–21–20; 8:45 am]
BILLING CODE 4410–09–P
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 21, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on February 26, 2020,
Noramco, Inc., 500 Swedes Landing
Road, Wilmington, Delaware 19801–
4417, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Marihuana ......................
Tetrahydrocannabinols ..
Codeine-N-oxide ............
Dihydromorphine ...........
Hydromorphinol .............
Morphine-N-oxide ..........
Amphetamine ................
Lisdexamfetamine .........
Methylphenidate ............
Nabilone ........................
Phenylacetone ...............
Codeine .........................
Dihydrocodeine ..............
Oxycodone ....................
Hydromorphone .............
Hydrocodone .................
Morphine ........................
Oripavine .......................
Thebaine ........................
Opium extracts ..............
Opium fluid extract ........
Opium tincture ...............
Opium, powdered ..........
Opium, granulated .........
Oxymorphone ................
Noroxymorphone ...........
Tapentadol .....................
Drug
code
7360
7370
9053
9145
9301
9307
1100
1205
1724
7379
8501
9050
9120
9143
9150
9193
9300
9330
9333
9610
9620
9630
9639
9640
9652
9668
9780
Schedule
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances as an
VerDate Sep<11>2014
18:07 May 21, 2020
Jkt 250001
DEPARTMENT OF JUSTICE
National Institute of Corrections
Advisory Board; Notice of Meeting
This notice announces a forthcoming
virtual meeting of the National Institute
of Corrections (NIC) Advisory Board.
The meeting will be open to the public.
Name of the Committee: NIC
Advisory Board.
General Function of the Committee:
To aid the National Institute of
Corrections in developing long-range
plans, advise on program development,
and recommend guidance to assist NIC’s
efforts in the areas of training, technical
assistance, information services, and
policy/program development assistance
to Federal, state, and local corrections
agencies.
Date and Time: 11:00 a.m.–1:30 p.m.
on Friday, June 19, 2020 (approximate).
Location: Virtual Platform.
Contact Person: Susan Walters,
Executive Assistant, National Institute
of Corrections, 320 First Street NW,
Room 901–3, Washington, DC 20534. To
contact Ms. Walters, please call (202)
353–4213.
Agenda: On Friday, June 19, 2020, the
Advisory Board will receive a brief
Agency Report from the NIC Acting
Director, with time for questions and
planning for subsequent FY20–FY21
Advisory Board meeting(s).
Procedure: On June 19, 2020, the
meeting is open to the public. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the committee. Written
submissions may be made to the contact
person on or before June 8, 2020. Oral
presentations from the public will be
scheduled between approximately 1:00
p.m. to 1:15 p.m. on June 19, 2020. Time
allotted for each presentation may be
limited. Those desiring to make formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
31227
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before June 8, 2020.
General Information: NIC welcomes
the attendance of the public at its
advisory committee meetings and will
make every effort to accommodate
persons with physical disabilities or
special needs. If you require special
accommodations due to a disability,
please contact Susan Walters at least 7
days in advance of the meeting. Notice
of this meeting is given under the
Federal Advisory Committee Act (5
U.S.C. app. 2).
Shaina Vanek,
Acting Director, National Institute of
Corrections.
[FR Doc. 2020–11051 Filed 5–21–20; 8:45 am]
BILLING CODE 4410–36–P
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Notice to
Employees of Coverage Options Under
Fair Labor Standards Act Section 18B
Notice of availability; request
for comments.
ACTION:
The Department of Labor
(DOL) is submitting this Employee
Benefits Security Administration
(EBSA)-sponsored information
collection request (ICR) to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995
(PRA). Public comments on the ICR are
invited.
DATES: The OMB will consider all
written comments that agency receives
on or before June 22, 2020.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Comments are invited on: (1) Whether
the collection of information is
necessary for the proper performance of
the functions of the Department,
including whether the information will
have practical utility; (2) if the
information will be processed and used
SUMMARY:
E:\FR\FM\22MYN1.SGM
22MYN1
]]>Agencies
[Federal Register Volume 85, Number 100 (Friday, May 22, 2020)]
[Notices]
[Page 31227]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11077]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-645]
Bulk Manufacturer of Controlled Substances Application: Noramco,
Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before July 21, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on February 26, 2020, Noramco, Inc., 500 Swedes Landing
Road, Wilmington, Delaware 19801-4417, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marihuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
Codeine-N-oxide........................ 9053 I
Dihydromorphine........................ 9145 I
Hydromorphinol......................... 9301 I
Morphine-N-oxide....................... 9307 I
Amphetamine............................ 1100 II
Lisdexamfetamine....................... 1205 II
Methylphenidate........................ 1724 II
Nabilone............................... 7379 II
Phenylacetone.......................... 8501 II
Codeine................................ 9050 II
Dihydrocodeine......................... 9120 II
Oxycodone.............................. 9143 II
Hydromorphone.......................... 9150 II
Hydrocodone............................ 9193 II
Morphine............................... 9300 II
Oripavine.............................. 9330 II
Thebaine............................... 9333 II
Opium extracts......................... 9610 II
Opium fluid extract.................... 9620 II
Opium tincture......................... 9630 II
Opium, powdered........................ 9639 II
Opium, granulated...................... 9640 II
Oxymorphone............................ 9652 II
Noroxymorphone......................... 9668 II
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
as an Active Pharmaceutical Ingredient (API) for supply to its
customers. In reference to drug codes 7360 (Marihuana) and 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as synthetics. No other activities for these drug codes are
authorized for this registration. This notice does not constitute an
evaluation or determination of the merits of the company's application.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-11077 Filed 5-21-20; 8:45 am]
BILLING CODE 4410-09-P
